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Edited by Varda RotterAbstract By GST pull downs and co-immunoprecipitation
analyses we found that recombinant Chk2 and HDM2 can form
stable complexes in vitro. Chk2/HDM2 complexes were also de-
tected in transfected Cos-1 cells over-expressing both proteins.
Furthermore, we show that HDM2, as would be expected, se-
verely aﬀects the Chk2-catalyzed phosphorylation of p53.
HDM2 itself is only slightly phosphorylated by Chk2. However,
whereas HDM2 inhibits the Chk2-catalyzed p53 phosphoryla-
tion, HDM2 phosphorylation by Chk2 doubles in the presence
of p53. The signiﬁcance of the HDM2 phosphorylation is un-
known, but it is possible that it might inﬂuence the stability of
the HDM2/p53 complex.
 2005 Federation of European Biochemical Societies. Published
by Elsevier B.V. All rights reserved.
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Phosphorylation1. Introduction
P53 regulation has been the subject of intense research over
many years. Besides being phosphorylated by a plethora of dif-
ferent protein kinases [1], modiﬁcations such as acetylation [2],
sumoylation [3], and proteolytic processing [4,5], also serve to
regulate p53 function. Among the many protein kinases target-
ing p53 is checkpoint kinase 2, Chk2 [6].
Upon Chk2/p53 interaction, p53 causes allosteric changes in
Chk2, in order for p53 itself to become a substrate despite the
lack of a classical Cdc25 consensus sequence for Chk2 [7].
HDM2, which is involved in the control of p53, has been
shown to undergo dynamic conformational changes upon li-
gand binding [8], and it was also shown that the phosphoryla-
tion status of p53 modulates its aﬃnity for HDM2 and other
proteins such a p300. HDM2 binds to the box I domain lo-
cated at the N-terminal part of the p53 molecule, where at least
three diﬀerent protein kinase phosphorylation sites, i.e. S15,
T18 and S20 are located. Although Chk2 interacts with the
box II and box V domains of p53, it phosphorylates T18
and S20 in box I. Therefore, one could expect an interference
of p53 phosphorylation with HDM2 binding, and likewise the
presence of HDM2 would be expected to aﬀect protein kinases
targeting amino acid residues in the box I domain, i.e. ATM
[9], Chk1/Chk2 [6] and CK1 [10]. Since one of the major inter-*Corresponding author.
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wanted to ﬁnd out how the Chk2-mediated phosphorylation
of p53 may be inﬂuenced by HDM2. Interaction between
p53/HDM2 [11] and p53/Chk2 have been described [12], yet
so far no interaction between Chk2 and HDM2 has been
reported.
We have used recombinant human proteins and performed
in vitro association analyses involving HDM2/Chk2. Corre-
sponding studies in cells over-expressing these proteins were
also performed. Here, we show that Chk2 and HDM2 can
physically interact, and that HDM2 can serve as a weak sub-
strate for Chk2. In the presence of HDM2, Chk2-mediated
phosphorylation of p53 is severely reduced, whereas HDM2
phosphorylation is increased by a factor of 2 in the presence
of p53.2. Materials and methods
2.1. Antibodies and western blotting
The following antibodies were used: polyclonal anti-Chk2 (H-300)
(Santa Cruz Biotechnology Inc.) and monoclonal anti-Chk2 (clone
7) (Upstate). Monoclonal anti-MDM2 (SMP14) (Santa Cruz) and rab-
bit, polyclonal anti-HDM2 (produced by immunisation of rabbits with
an HDM2 peptide). Western blotting was performed as described in
[13].
2.2. Plasmid constructs
Human Chk2 cDNA was cloned into the pQE-TriSystem vector
(QIAGEN) (His-tag) and into pGEX-6P-C (Amersham Pharmacia
Biotech), adding a Glutathione S transferase (GST) tag. Human
chk2 in pcDNA3.1 was a gift from Dr. James Hutchins (University
of Dundee, UK). Hdm2 cDNA was cloned in pMAL-c2X (New
England Biolabs), adding a maltose binding protein (MBP) tag, in
pGEX-2T (Amersham) for GST tagging and in pSG5 for mammalian
expression.
Human p53 in pET-3a was a gift from Dr. Lisa Wiesmu¨ller (Univer-
sita¨t Ulm, Germany). The p53 sequence was sub-cloned into pET-19b
(Novagen), for His-tagging.
2.3. Expression and puriﬁcation of Chk2
The BacVector-3000 Transfection Kit was purchased from Nova-
gen. Production of recombinant baculovirus particles and expression
of Chk2 in Sf9 cells was performed as recommended by the manufac-
turer. 72 h post-infection, Sf9 cells were lysed by sonication in 25 mM
Tris–HCl pH 8.5, 1 mM DTT, 100 mM NaCl, protease inhibitors
(Complete, Roche), and Chk2 was puriﬁed by Ni-NTA agarose (QIA-
GEN) chromatography.
2.4. Expression and puriﬁcation of bacterially expressed proteins
MBP-HDM2 was expressed in TB1 cells and puriﬁed by aﬃnity
chromatography on an amylose column (New England Biolabs), fol-
lowing the manufacturers recommendations.blished by Elsevier B.V. All rights reserved.
Fig. 1. Interaction between Chk2 and HDM2 in vitro. (A) Bacterially
expressed GST (lane 1) or GST-Chk2 (lane 2) was immobilized on
Glutathione–Sepharose beads and incubated with MBP-HDM2.
Interaction was analyzed by Western blot detection of MBP-HDM2.
In lane 3, MBP-HDM2 was loaded directly on the gel as a positive
control. (B) Bacterially expressed GST (lane 2) or GST-HDM2 (lane 3)
was immobilized on Glutathione–Sepharose beads and incubated with
in vitro transcribed and translated (IVTT) [35S]-labelled Chk2.
Interaction was detected by SDS–PAGE followed by autoradiography.
In lane 1 in vitro translated Chk2 was loaded directly on the gel as a
positive control. (C) In vitro immunoprecipitations with equal molar
amounts of puriﬁed, recombinant MBP-HDM2 (0.7 lg) and Chk2-His
(1 lg-dimer). Precipitation was performed with rabbit pre-immune
serum (lane 1), rabbit polyclonal Chk2-antibody (lane 2), or mono-
clonal MDM2-antibody (lane 3). Precipitates were analyzed by
Western blot detection of Chk2 and HDM2, using monoclonal
antibodies. The background signal is quite high in the upper part of
lane 3, because the same monoclonal antibody (SMP14) was used for
both immunoprecipitation and Western blot detection of HDM2.
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was insoluble, and it was solubilized and refolded as described by Bell
et al. [14]. Refolded p53 was then puriﬁed by Ni-NTA (QIAGEN)
aﬃnity chromatography.
His-tagged MDM2 was a gift from Dr. Mathias Montenarh (Uni-
versita¨t des Saarlandes, Germany).
2.5. In vitro translation of Chk2
Chk2 was transcribed and translated in vitro from the pcDNA3.1
vector using the TnT Quick coupled Transcription/Translation System
(Promega).
2.6. GST pull downs
GST-Chk2, GST-HDM2 and GST were expressed in DH5a cells.
Bacteria were lysed by sonication in 50 mM Tris–HCl pH 7.5, 10% su-
crose, 50 mMNaCl, protease inhibitors (Complete, Roche), and debris
was removed by centrifugation. Various volumes of the individual ex-
tracts were incubated with Glutathione–Sepharose 4B beads, and after
elution from the beads the amounts of GST fusion proteins from each
extract were compared by SDS–polyacrylamide gel electrophoresis
(SDS–PAGE). Equal amounts of the GST fusion proteins were then
immobilized on Glutathione–Sepharose 4B beads (Amersham Biosci-
ences) and incubated with interaction partners in binding buﬀer
(20 mM Tris–HCl pH 7.5, 100 mM NaCl, 2 mM EDTA, 0.1% Igepal,
2 mM DTT, 0.05% BSA, 5% glycerol, and protease inhibitors (Com-
plete, Roche)) for 2 h at 4 C. Bound proteins were eluted with 25 ll
SDS sample buﬀer, separated by SDS–PAGE and analyzed by Wes-
tern blotting for detection of MBP-HDM2, or by autoradiography
for detection of [35S]-labelled, in vitro translated Chk2.
2.7. Cos-1 cell culture and transfection
Cos-1 cells were maintained in Dulbeccos MEM (Gibco BRL) sup-
plemented with 10% fetal bovine serum (Bio Whittaker Europe) and
non-essential amino acids (Gibco BRL).
Cells were transfected with plasmid DNAs using jetPEI transfection
reagent (PolyPlus transfection).
2.8. Immunoprecipitation
Immunoprecipitation was performed essentially as described previ-
ously [15], using monoclonal MDM2 antibody, polyclonal Chk2 anti-
body or rabbit pre-immune serum. Precipitated proteins were detected
by Western blotting using the antibodies indicated in the ﬁgure leg-
ends.
2.9. Phosphorylation assays
For phosphorylation assays we used 250 ng Chk2 and 3 lg p53 (or
6.3 lg MBP-HDM2) as the substrate. Increasing amounts of MBP-
HDM2 (0.79–6.3 lg) were added. As a negative control BSA (A-
4503, Sigma) (4.3 lg) was used, and as a control for eﬀects of the
MBP-tag, we used His-MDM2 (0.45 lg – corresponding to 0.79 lg
MBP-HDM2 in molar amounts).
Proteins were mixed in Kinase buﬀer (10 mM MOPS pH 7.0,
0.5 mM EDTA, 50 lM ATP, and 7.5 mM MgCl2). MBP-HDM2,
His-MDM2 or BSA interacted with p53 for 20 min on ice, then
Chk2 and 5 lCi [c-32P] ATP (3000 Ci/mmol, Hartmann Analytic) were
added (total volume: 15 ll), and reactions were incubated at 30 C for
30 min. Phosphorylation was terminated by addition of SDS-sample
buﬀer. Proteins were separated by SDS–PAGE and subjected to auto-
radiography. Radioactivity incorporated into individual proteins was
quantiﬁed by scintillation counting of excised protein bands.3. Results and discussion
3.1. Analyses of interaction between Chk2 and HDM2
To determine whether Chk2 was able to interact directly
with HDM2, we performed GST – pull down experiments
and in vitro immunoprecipitations (Fig. 1). First, recombinant
GST and GST-Chk2 immobilized on Glutathione–Sepharose
4B beads were incubated with a bacterial extract of MBP-HDM2, and interaction was analyzed by Western blot detec-
tion of HDM2 (Fig. 1A). MBP-HDM2 interacted with GST-
CHK2 (Fig. 1A, lane 2), whereas it did not interact with
GST alone (Fig. 1A, lane 1), proving that interaction of
MBP-HDM2 was Chk2 speciﬁc and not due to interaction
with the GST tag. The GST pull downs were repeated, using
GST and GST-HDM2 immobilized on Glutathione–Sephar-
ose 4B beads and in vitro translated [35S]-labelled Chk2 as
the interaction partner (Fig. 1B). Again we found a speciﬁc
interaction between GST-HDM2 and Chk2-MycHis (Fig.
1B, lane 3), whereas Chk2 did not interact with GST (Fig.
1B, lane 2), proving that the above observed interaction be-
tween GST-Chk2 and MBP-HDM2 is independent of the
MBP-tag as well as the GST tag.
Additionally, we performed in vitro immunoprecipitations
with puriﬁed Chk2-His and MBP-HDM2 (Fig. 1C), showing
a speciﬁc interaction between Chk2 and MBP-HDM2. Large
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antibody (Fig. 1C, lane 2); whereas it should be mentioned that
only a weak signal corresponding to Chk2 could be observed
after immunoprecipitation of MBP-HDM2 (Fig. 1C, lane 3).
Next we asked the question, whether the interaction between
Chk2 and HDM2 would also take place in intact mammalian
cells. Cos-1 cells were co-transfected with HDM2 and Chk2,
and successful transfection was veriﬁed by Western blotting
(Fig. 2A).
HDM2 was then immunoprecipitated from transfected Cos-
1 cells, and a weak but signiﬁcant co-precipitation of Chk2 was
detected (Fig. 2B). As can be observed in Fig. 2B, lane 2 (upper
part), the precipitation of HDM2 from the Cos-1 cells was not
very eﬃcient, and thus the band corresponding to co-precipi-
tated Chk2 (Fig. 2B, lane 2, lower part) is also quite weak.
Unfortunately, when performing immunoprecipitations of
Chk2 from the transfected Cos-1 cells, we observed a quite
strong unspeciﬁc binding of HDM2, also in the negative con-
trol reaction, and thus we could not use these results to show
interaction between Chk2 and HDM2.
However, based on the results obtained by immunoprecipi-
tation of HDM2 we conclude that Chk2 and HDM2 are able
to interact in transfected mammalian cells although our results
indicate that the interaction likely only aﬀects a small sub-pop-
ulation of the two proteins.
To prove that the observed interaction between Chk2 and
HDM2 is indeed potentially physiologically signiﬁcant, we
would have to show interaction also between the endogenousFig. 2. Interaction between Chk2 and HDM2 in cultured cells.
(A) Western blot detection of Chk2 and HDM2 in Cos-1 cells
transfected with empty vector (lane 1) or with Chk2 plus HDM2 (lane
2). (B) Immunoprecipitation of HDM2 from co-transfected Cos-1 cells
by monoclonal MDM2-antibody (lane 2). As a negative control, rabbit
pre-immune serum (lane 1) was used for immunoprecipitation.
Precipitates were analysed by Western blot detection of HDM2 and
Chk2, using rabbit polyclonal anti-HDM2 antibody and monoclonal
anti-Chk2 antibody. The strong band in the upper part of lane 1 is not
HDM2 as it does not run at the same molecular mass as HDM2.
Instead the band is likely an artefact resulting from using rabbit pre-
immune serum for immunoprecipitation and subsequently also a
rabbit polyclonal antibody for Western blotting.proteins in non-transfected cells. However, this was very diﬃ-
cult to do, since endogenous HDM2 has a rapid turnover and
is generally diﬃcult to detect. Endogenous HDM2 was detect-
able in the Cos-1 cells after relatively long exposure times of
Western blots, but unfortunately the expression of Chk2 is
very low in these cells, making them unsuited for interaction
studies. Additionally, as observed for the transfected Cos-1 ex-
tracts, our anti-MDM2 antibody (SMP14) was not able to pre-
cipitate very large amounts of HDM2, even when the protein
was over-expressed, and since the interaction between Chk2
and HDM2 likely only aﬀects a small sub-population of the
two proteins, we do not expect to be able to detect Chk2 in
immunoprecipitates of endogenous HDM2. Often HDM2 is
stabilized in cell lines by incubation with proteasome inhibi-
tors, and this would be a possible means of increasing the
amount and detection of HDM2, but on the other hand, like
transfection, this would not be a physiological situation.
Thus, we did not show interaction between endogenous
Chk2 and HDM2, and therefore we cannot be sure if the inter-
action observed is physiologically signiﬁcant.3.2. Chk2 phosphorylation assays
We analyzed whether MBP-HDM2 could serve as a sub-
strate for Chk2 (Fig. 3A) in an in vitro phosphorylation assay,
and as a positive control, p53 was also phosphorylated by
Chk2. Compared to the phosphorylation of p53 MBP-
HDM2 was only weakly phosphorylated by Chk2, even
though four times as much MBP-HDM2 was used compared
to tetrameric p53 on a molar basis. Thus, MBP-HDM2 is
not a good substrate for Chk2 in vitro. However, HDM2
might be a better substrate for Chk2 in vivo, and a possible
physiological relevance of the observed phosphorylation has
to be further addressed. In support of a possible physiological
relevance, we found that even though MBP-HDM2 was a very
weak substrate of Chk2 on its own, its phosphorylation was in-
creased 2.1 fold in the presence of p53 (Fig. 3A and D).
We could exclude that the observed phosphorylation of
MBP-HDM2 might be located at the MBP-tag, since we found
that the control His-MDM2 protein was on average 1.6 fold
more phosphorylated than the corresponding amount of
MBP-HDM2 (Fig. 3E). Based on these ﬁndings, we speculate
that the MBP tag may in fact inhibit Chk2-mediated phos-
phorylation of HDM2 rather than serve as a target for phos-
phorylation itself. However, an alternative explanation for
the higher phosphorylation of His-MDM2 compared to
MBP-HDM2 could be that mouse MDM2 may be a better
substrate for Chk2 than the human homolog, HDM2.
Next we analyzed whether interaction with MBP-HDM2
might inﬂuence the activity of Chk2 toward other substrates
in vitro. Chk2 kinase assays, employing the synthetic substrate
peptide, Chktide, were performed with addition of increasing
amounts of MBP-HDM2 to the reaction. However, no signif-
icant eﬀect of MBP-HDM2 on the Chk2-mediated phosphor-
ylation of Chktide could be observed (results not shown).
This does not come as a surprise, since small peptides must
not necessarily mimic the complex domain structure found in
a full length protein. However, in any case this result indicates
that MBP-HDM2 does not directly inﬂuence the active site in
Chk2.
We then analysed the eﬀects of HDM2 with respect to Chk2-
mediated phosphorylation of p53 by adding increasing
Fig. 3. Phosphorylation assays. (A) Autoradiograph showing Chk2-mediated phosphorylation of p53 (3 lg) (lane 1), MBP-HDM2 (6.3 lg) (lane 2),
or a mixture of the two proteins (lane 3). (B) Autoradiograph showing the eﬀect of adding BSA at four times the molar amount of p53 to the Chk2-
p53 phosphorylation assay. (C) Quantitative analysis of the inﬂuence of MBP-HDM2, BSA and His-MDM2 on the Chk2-mediated phosphorylation
of p53. Increasing amounts of MBP-HDM2 (1/2 – four times the molar amount of p53 tetramer) were added to the Chk2/p53 phosphorylation
reactions. The phosphorylation of p53 is given as a ratio to the autophosphorylation of Chk2 (p53-P/Chk2-P). Phosphorylation of p53 in the
presence of BSA, His-MDM2 or MBP-HDM2 was calculated as a percentage of the phosphorylation of p53 in the absence of these proteins. The
histogram is based on the results of six independent experiments (four for His-MDM2), and the standard errors are shown by error bars. (D)
Quantitative analysis of the Chk2-catalyzed phosphorylation of MBP-HDM2 in the absence and presence of p53, where the phosphorylation of
MBP-HDM2 in the absence of p53 was set to 1. The histogram is based on six independent experiments, and the standard error is shown by an error
bar. (E) Comparison of the Chk2-catalyzed phosphorylation of equal molar amounts of MBP-HDM2 and His-MDM2. Phosphorylation of MBP-
HDM2 was set to 1, and the histogram is based on four individual experiments. Again the standard error is shown by an error bar. (F) Alignment of
the activation domain (MDM2-binding domain) of human p53 with the MDM2 lid, modiﬁed from Shimizu and Hupp [19]. Homology between the
human MDM2 lid and the MDM2 binding domain on p53 is shown in bold characters.
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reaction (Fig. 3C). Already in the presence of half the molar
amount of MBP-HDM2 compared to p53, the phosphoryla-
tion of p53 was reduced to 67% of the phosphorylation in
the absence of MBP-HDM2, and addition of four times
MBP-HDM2 resulted in reduction of the p53 phosphorylation
to 32% (Fig. 3C). On the other hand, addition of four times
more BSA than p53 in molar amounts did not aﬀect the phos-
phorylation of p53 signiﬁcantly, suggesting that the eﬀect is
speciﬁc for MBP-HDM2 (Fig. 3B and C). Additionally, whenusing His-MDM2 as a control for the eﬀect of the large MBP-
tag (42 kDa), a reduction in p53 phosphorylation comparable
to, but on average a little weaker than that observed with the
same molar amount of MBP-HDM2, was found (Fig. 3C),
indicating that the inhibition of p53 phosphorylation was not
largely dependent of the MBP-tag, but rather HDM2 speciﬁc.
The excess amount we have chosen in this experiment re-
ﬂects the over-expression of HDM2 often detected in sarco-
mas, leukaemia, and malignancies of the breast and prostate
[16].
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of p53 in the presence of HDM2 agrees well with the fact that
HDM2 interacts with the transactivation domain (box I do-
main) of p53 [17], which contains the target sites (T18 and
S20) for Chk2 phosphorylation [6,7,9]. Based on these facts,
binding of HDM2 would be expected to inhibit phosphoryla-
tion of p53 at these sites. However, a complete inhibition of
p53 phosphorylation was not achieved in this assay, even when
four times the molar amount of HDM2 compared to p53 tet-
ramers, which would be expected to saturate p53 with HDM2,
was added. It is possible that the association between p53 and
HDM2 in the assay is not complete or that interaction com-
plexes exist as an equilibrium with the two proteins in free
form, which could lead to some phosphorylation of p53. Fur-
thermore, it is possible that Chk2 might also phosphorylate
additional sites in p53, which are not blocked by HDM2.
Craig et al. [7] have shown that the box II and V domains of
p53 are able to allosterically activate the catalytic activity of
Chk2 toward T18 and S20 in the N-terminal box I domain
of p53. Additionally they found that the p21 protein, which
shows homology with the box I domain of p53, became a sub-
strate of Chk2 in the presence of the box II and V peptides of
p53 [7]. Furthermore, it has recently been shown that regula-
tion of the MDM2-p53 complex involves a ﬂexible ‘‘lid’’,
which can close over the hydrophobic pocket of MDM2 that
interacts with p53 [18]. As reviewed by Shimizu and Hupp
[19] this peptide lid shows homology to the p53 activation do-
main (Fig. 3F), suggesting that it might be able to compete in
cis for binding with p53 and act as a pseudo-substrate domain.
Phosphorylation of the SQ motif within this lid by DNA-PK
(or ATM) disrupts the p53-MDM2 complex, very likely by sta-
bilizing the interaction of the lid with MDM2 and alteration of
the MDM2 conformation [19].
Our results show that HDM2 becomes a better substrate for
Chk2 in the presence of p53, which may be based on the homol-
ogy between the peptide lid of HDM2 and the p53 transactiva-
tion domain. Hence, this phosphorylation of HDM2 may, like
the phosphorylation ofMDM2 by DNA-PK (or ATM), lead to
dissociation of p53 and HDM2 and thus interfere with the neg-
ative feedback loop controlling p53 stability and HDM2
expression. Although speculative at the moment it would be
interesting to analyse, whether Chk2 does in fact phosphorylate
the peptide lid of HDM2 and likewise, if this phosphorylation
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